Ropinirole for antidepressant-induced sexual dysfunction

Int Clin Psychopharmacol. 2002 Nov;17(6):307-10. doi: 10.1097/00004850-200211000-00006.


Sexual dysfunction is a relatively common side-effect of antidepressants, occurring in approximately one-half of patients, and is associated with significant distress and treatment non-compliance. Dopaminergic agents have been reported to be helpful for the treatment of antidepressant-induced sexual dysfunction and, in this report, we examined the efficacy of the dopamine agonist ropinirole for this indication. Thirteen patients (three women, 10 men), aged 42.6 +/- 7.7 years, who reported sexual dysfunction on a stable dose of antidepressant, were treated openly with ropinirole initiated at 0.25 mg/day and titrated up to 2-4 mg/day over 4 weeks, as tolerated. Ten of the 13 took ropinirole for at least 4 weeks, one discontinued due to an adverse event and two because of lack of response. Sexual dysfunction, as assessed by the Arizona Sexual Experience Scale scores, was reduced from 18.8 +/- 3.6 to 13.8 +/- 4.3 after 4 weeks on ropinirole at a mean dose of 2.1 mg/day. Overall, seven of 13 patients (54%) were rated as responders on the Clinical Global Impression of Improvement Scale. The addition of ropinirole may represent a potentially useful treatment strategy for antidepressant-induced sexual dysfunction.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Antidepressive Agents / adverse effects*
  • Antiparkinson Agents / pharmacology*
  • Anxiety
  • Depressive Disorder / drug therapy*
  • Female
  • Humans
  • Indoles / pharmacology*
  • Male
  • Middle Aged
  • Patient Compliance
  • Severity of Illness Index
  • Sexual Dysfunction, Physiological / chemically induced*
  • Sexual Dysfunction, Physiological / drug therapy*
  • Treatment Outcome


  • Antidepressive Agents
  • Antiparkinson Agents
  • Indoles
  • ropinirole